

## Body Surface Mapping to Guide Atrial Fibrillation Ablation

Seigo Yamashita,<sup>1</sup> Ashok J Shah,<sup>1</sup> Saagar Mahida,<sup>1</sup> Jean-Marc Sellal,<sup>1</sup> Benjamin Berte,<sup>1</sup> Darren Hooks,<sup>1</sup> Antonio Frontera,<sup>1</sup> Nora Al Jefairi,<sup>1</sup> Jean-Yves Wielandts,<sup>1</sup> Han S Lim,<sup>1</sup> Sana Amraoui,<sup>1</sup> Arnaud Denis,<sup>1</sup> Nicolas Derval,<sup>1,2</sup> Frédéric Sacher,<sup>1,2</sup> Hubert Cochet,<sup>2,3</sup> Méléze Hocini,<sup>1,2</sup> Pierre Jaïs<sup>1,2</sup> and Michel Haïssaguerre<sup>1,2</sup>

1. Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France; 2. Institut Liryc/Equipex Music, Université de Bordeaux-Inserm U1045, Pessac, France; 3. Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, Pessac, France

### Abstract

Atrial fibrillation (AF) is the most common rhythm disorder, and is strongly associated with thromboembolic events and heart failure. Over the past decade, catheter ablation of AF has advanced considerably with progressive improvement in success rates. However, interventional treatment is still challenging, especially for persistent and long-standing persistent AF. Recently, AF analysis using a non-invasive body surface mapping technique has been shown to identify localised reentrant and focal sources, which play an important role in driving and perpetuating AF. Non-invasive mapping-guided ablation has also been reported to be effective for persistent AF. In this review, we describe new clinical insights obtained from non-invasive mapping of persistent AF to guide catheter ablation.

### Keywords

Ablation, atrial fibrillation, body surface mapping, driver, non-invasive

**Disclosure:** Michel Haïssaguerre, Pierre Jaïs and Méléze Hocini are stockholders in Cardiolsight Inc and Ashok J Shah is a paid consultant to Cardiolsight Inc. The remaining authors have no conflicts of interest to declare.

**Received:** 21 July 2015 **Accepted:** 18 November 2015 **Citation:** *Arrhythmia & Electrophysiology Review* 2015;**4**(3):172–6. **Access at:** [www.AERjournal.com](http://www.AERjournal.com)

**Correspondence:** Michel Haïssaguerre, Hôpital Cardiologique du Haut-Lévêque Avenue de Magellan, Bordeaux-Pessac, 33604, France.

E: [michel.haissaguerre@chu-bordeaux.fr](mailto:michel.haissaguerre@chu-bordeaux.fr)

Catheter ablation therapy has been widely used for rhythm control in patients with atrial fibrillation (AF).<sup>1</sup> Since the first report in 1994,<sup>2</sup> several interventional techniques have been proposed for AF, including replication of the surgical Maze,<sup>2</sup> targeting pulmonary vein (PV) foci,<sup>3</sup> segmental ostial and circumferential PV isolation,<sup>4,5</sup> ganglionated plexi ablation,<sup>6</sup> linear lesions in the left atrium (LA),<sup>7</sup> complex fractionated atrial electrogram (CFAE)-based ablation<sup>8</sup> and a stepwise approach.<sup>9</sup> PV isolation remains the cornerstone of paroxysmal AF ablation and has a high success rate. In persistent AF, its role is limited because of the additional involvement of LA substrate due to extensive electrical and anatomical remodelling. The understanding of the substrate maintaining AF leads to the concept of pre-existing specific fibrotic atrial cardiomyopathy. The presence of fibrosis causing changes in cellular coupling results in spatial non-uniform anisotropic impulse propagation, which is a potential cause of abnormal atrial activation underlying the initiation and perpetuation of reentrant arrhythmia-like AF.<sup>10,11</sup> In view of these changes underlying persistent AF, several ablation strategies have been attempted to modify the atrial substrate. While there has been some improvement in clinical outcomes,<sup>6–9</sup> factors such as undue radiofrequency (RF) application, long procedural duration and high incidence of post-procedural atrial tachycardia (AT) remain.<sup>12</sup>


Recently, AF mapping using activation<sup>13</sup> or phase-based<sup>14</sup> analysis of body surface potentials, has allowed potential visualisation of AF-driving substrate in the form of multiple wavelets and reentrant drivers. Prior knowledge of the main AF-driving regions has been shown to facilitate the ablation procedure in patients with persistent AF.<sup>14</sup>

### Non-invasive Body Surface Mapping Analysis for Atrial Fibrillation

From the previous investigations, multiple atrial wavelets, macro-reentries and localised sources (focal or reentry) have been reported to lead to maintenance of AF.<sup>15,16</sup> Electrical activities in the myocardium during AF can be mapped with electrode arrays in the *in situ* heart<sup>17</sup> and voltage-sensitive fluorescent dyes in the isolated heart,<sup>18</sup> which demonstrate complex and often irregular activity. A study involving epicardial mapping of induced human AF demonstrated multiple dynamic wave fronts interacting with changing arcs of conduction block and slow conduction.<sup>19</sup> Another recent study mapping chronic AF intraoperatively demonstrated short regular cycle length that could be consistent with a driver with irregular activation of the rest of the atrium.<sup>20</sup> Although it is now well accepted that the irregular waveform is seen from an irregular and constantly changing activation sequence on the surface electrogram during AF, these drivers are practically difficult to detect with conventional techniques because of the continuous and intermittent spatiotemporal dynamicity of underlying sources.<sup>21,22</sup> To assess driver activities, phase analysis has been applied to these signals. Due to the wavefront interactions leading to constant fractionation and collision, phase mapping provides an amplitude-independent manner to characterise and visualise dynamic data.<sup>23</sup> Non-invasive mapping enables panoramic beat-to-beat mapping of this dynamic rhythm using phase analysis.<sup>9,14</sup>

Electrocardiographic imaging, which non-invasively images cardiac electrical activity in the heart, has been developed recently.<sup>24–26</sup> This novel modality can demonstrate reconstructed unipolar electrical potentials, electrograms and isochrones on the epicardium by using

Figure 1: Processing of Body Surface Mapping




(A) After acquiring CT scan with the 252 electrode vest; (B) multiple atrial fibrillation (AF) windows with subtraction of QRST are analysed to identify consistent drivers by using phase map analysis. (C) The cumulative epicardial driver map is composed on the reconstructed biatrial shell from CT. Density of the driver map is based on the prevalence and trajectory of the reentrant driver core. AP = anterior-posterior ; PA = posterior-anterior

geometrical information from computed tomography (CT) and an inverse mathematical algorithm.<sup>27</sup> Based on the inverse principle, the clinical utility of non-invasive body surface mapping in atrial and ventricular arrhythmias has been reported.<sup>28-31</sup> Body surface mapping is undertaken by using a commercially available system (ECVUETM, Cardioinsight Technologies). After acquiring 64 section multi-detector CT images with a vest of 252 body-surface electrodes positioned on the thorax and upper abdomen, epicardial unipolar electrograms are reconstructed on a patient-specific biatrial geometry.<sup>27</sup> AF electrograms are acquired during a long ventricular pause – spontaneous or diltiazem-provoked. QRST is subtracted and AF maps are created using specific algorithms combining wavelet transform and phase mapping applied to the reconstructed epicardial potentials. Activation maps are computed using traditional unipolar electrogram intrinsic deflection-based (dV/dT)max method. The AF drivers can be classified into two categories: (i) focal activation with centrifugal propagation from a point and (ii) reentry/rotor demonstrating rotated wave with full-phase propagation around a functional or anatomical centrepoin. The core and trajectory of reentrant drivers and focal sources are depicted on the patient-specific biatrial geometry (see Figure 1A–C).<sup>28,32</sup> The number of foci and reentry through the total duration of all AF windows are displayed on cumulative driver-density maps.

**Distribution and Characteristics of Localised Driver**

Non-invasive mapping reveals multiple locations of drivers in persistent AF. These drivers demonstrate abrupt appearance at single or multiple sites and reproducibly rotate few times, often showing meandering motion spatiotemporally. In our previous report,<sup>14</sup> repetitive reentrant activities (>1 rotation) were observed in 73 % of reentrant drivers with median 2.6 (interquartile range 2.3–3.3) repetitive rotations. The trajectory of reentrant driver core was spread over mean 7±2 cm<sup>2</sup>; accordingly the map displays driver location not at a discrete site, but over a certain area with variable density (see Figure 1C). The drivers were located in PVs and their respective antra in about 90 % patients in paroxysmal AF where approximately 50 % of patients demonstrated non-PV foci and reentry.<sup>33</sup> In persistent AF left PV-appendage (ridge), right PV/septum and inferior LA were most common locations of reentrant driver. Focal driver originated from PV ostium and right or left appendages with a median of four regions.<sup>14</sup> The prevalence and distribution of drivers depend on the clinical duration of AF such that the total number of driver regions and


Figure 2: Significance of Number of Driver Regions



(A) The median number of driver regions. (B) Relationship between radiofrequency (RF) time for atrial fibrillation (AF) termination and number of driver regions (upper). RF time for AF termination significantly correlated to number of driver regions (p<0.001). While RF time inversely collated to cycle length of left atrial appendage (r=-0.52; p<0.001) (lower). (C) Typical examples of driver map in patients with and without acute success. The cases with AF termination demonstrated a fewer number of reentrant drivers, smaller left atrium and longer cycle length of left/right atrial appendage compared with non-AF termination cases. CL = cycle length; LA = left atrium; LAA = left atrial appendage; LSPV = left superior pulmonary vein; RF = radiofrequency.


activities increase with the length of continuous AF (see Figure 2A), indicating that the driver characteristics are associated with the extent of atrial remodelling. Previous reports demonstrated that longstanding AF had a larger LA surface with a greater amount of total scar (delayed enhancement area on magnetic resonance imaging [MRI]) and more continuous CFAE surface area than persistent AF.<sup>34</sup> The relationship between CFAE sites and localised drivers is not clear. In our study, prolonged fractionated electrograms were more frequently observed at the reentrant driver regions compared with non-driver regions (62 % versus 40 %; p=0.04). Additionally electrograms recorded on a multi-electrode catheter covered most of the AF cycle length at the driver regions, which indicate towards the possibility of localised reentry.<sup>14</sup> Of note, multi-electrode endocardial mapping was not performed simultaneously with the body surface mapping. Of note, 50 % of CFAE sites

Figure 3: Driver-based Ablation



(A) Targeted signal and endpoint of local radiofrequency (RF) application. The rapid and fragmented potentials in the driver area are targeted. The endpoint of RF application is organisation of the local fragmented signals and slowing of the local AF cycle length at the RF site. (B) A typical example of driver-based ablation. In this case, based on the body surface mapping result, left atrial inferior was targeted at first because of high density of reentrant drivers and the fact that fragmented activities were observed in the coronary sinus, left atrial septum; ridge and anterior were then followed. Finally atrial fibrillation terminated at left atrial anterior (blue spot).

Figure 4: Typical Examples of Repeat Mapping



The results of repeat mapping after ablation showed three different patterns: (1) Elimination of the targeted driver by effective ablation (red dotted circle); (2) persistence of the targeted driver indicating insufficient local ablation and requiring additional RF applications at the same region (blue dotted circle); and (3) new driver appearance at a contiguous or completely different region (yellow dotted circle). ABL = .ablation

have been reported to be passive bystanders due to non-local signal or wave collisions.<sup>35,36</sup> Non-invasive mapping may be considered to reveal critical CFAE sites harbouring localised AF drivers. Interestingly, a previous report showed that 89 % of CFAE sites were located at non-scar and patchy scar areas (41 % at patchy fibrosis area; 48 % at healthy area).<sup>34</sup> Another study demonstrated that localised reentrant drivers are located at the border of fibrotic areas,<sup>37</sup> with the good correlation between LA fibrosis burden and the number of localised reentrant driver regions ( $r=0.42$ ;  $p=0.04$ ). It suggested that the border zone of fibrosis allows formation of a substrate favourable for slow conduction and reentry of wavelets (reentrant driver) capable of perpetuating AF.<sup>37</sup>

## Non-invasive Mapping-guided Ablation

The order of ablation is determined based on the cumulative driver map (see Figure 1C). After acquiring atrial geometry on 3D-electroanatomical mapping system (CARTO3; Biosense Webster Inc), the region having the highest density of reentrant drivers is targeted first followed by the region with the second-highest driver density and so on. Within the driver area, rapid and continuous fragmented signals and the activation gradient between proximal and distal electrodes are locally

mapped and targeted for ablation.<sup>38</sup> The endpoint of RF application is elimination of fragmented potential and slowing of the AF cycle length at the local site (see Figure 3A). Each RF application targets dominant clusters of AF driver at 30–40 W (25 W in posterior wall) using an irrigated-tip catheter with temperature cut-off set at 45°C. If AF persists after ablation of the first targeted region, the second-highest density area of driver is subsequently ablated in the same way (see Figure 3B). The endpoint of the procedure is AF termination (sinus rhythm [SR] or AT) or completion of RF applications targeting all driver areas. If the drivers are found to be present around PVs, ipsilateral PV isolation is routinely performed. Reentrant drivers are more preferentially targeted than focal drivers because of the fact that sites harbouring atrial focal activities during AF were not found to be strongly associated with AF termination.<sup>32</sup> Also, stable drivers with good quality signals on the non-invasive map are targeted regardless of their type. AF sustained after driver-based ablation is electrocardioverted.

## Acute and Long-term Clinical Outcome After Driver-guided Ablation

In our series of 103 persistent AF patients who underwent driver-based ablation,<sup>14</sup> AF terminated during the procedure in 82 (80 %) patients with RF duration of  $35 \pm 21$  minutes. The mode of termination was SR in 28 (34 %) and AT in 54 (66 %) patients. AF termination with only driver ablation without linear lesions was achieved in 65 (63 %) patients. The number of targeted region for AF termination increased with AF duration (three in AF lasting <3 months, four in AF lasting 4–6 months and six in AF lasting >6 months). Inversely, the termination rate decreased with AF duration (85 % in AF lasting <3 months, 82 % in AF lasting 4–6 months, 67 % in AF lasting 7–9 months, 36 % in AF lasting 10–12 months and 15 % in AF lasting >12 months). Moreover, the patients with SR at the beginning of the procedure demonstrated the highest termination rate of 88 %. An impressive finding of driver-based ablation is that high AF-termination rate was achieved with reduced RF-time compared with the stepwise approach ( $28 \pm 17$  versus  $65 \pm 33$ ;  $p < 0.0001$ ). At 12 months post ablation, 64 % of patients maintained SR and 22 % were in AT. In this study, 85 % patients with AF termination were free from AF at 1 year after the procedure, which was comparable to stepwise ablation strategy. Also, the AF-free survival rate was higher in patients with acute AF termination than non-termination (85 % versus 63 %;  $p=0.045$ ). In another population, RF time for AF termination increased with the number of driver regions and correlated to cycle length of left and right atrial appendages (see Figure 2B).<sup>39</sup> Continuous AF duration, left appendage cycle length, number of reentrant drives and surface area of LA were independent predictors of AF termination on multivariable analysis (see Figure 2C). These results suggest that driver-based ablation is feasible and effective in patients with persistent AF and those having progressed atrial remodelling with extended fibrosis (AF duration >12 months) continue to pose a challenge.

Recently, a prospective multicentre study (non-invasive mapping of atrial fibrillation study [AFACART]) demonstrated feasibility and utility of body surface mapping in persistent AF.<sup>40</sup> In this study, 118 persistent AF patients (AF duration <1 year) were enrolled among eight European centres that had no prior experience using non-invasive system for driver-guided ablation to evaluate its acute success rate, RF time and clinical outcome at 12 months. Acute success (AF termination) was achieved in 64 % patients by driver-based ablation with  $46 \pm 28$  minutes of RF time. During  $6 \pm 3$  months' follow-up, 83 % of patients were free from AF including recurrent AT




in 38 % patients. These results indicate that driver-guided ablation of persistent AF is feasible and its outcomes reproducible in centres with no prior experience.

### Limitation and Prospects of Body Surface Mapping

Non-invasive body surface mapping of AF drivers have some limitations: 1) Assessment of the drivers in the septal area is difficult. It is projected posteriorly on right atrium or anteriorly in the interatrial groove from right/left septum. These areas are close to each other and located under the epicardium making it difficult to identify driver area from body surface signals. 2) Agreement between driver areas and ablation sites may not be perfect because the body surface mapping system (ECVUE) does not have 3D-mapping navigation system. Although image integration with CARTO3 is possible, it may not be performed in all cases. 3) Accuracy of detection of small amplitude and very short cycle length (very rapid drivers) signals is not reliable because of the preset limits on the range of acceptable signal/noise ratio and window of analysable AF cycle length (4–8 Hz). The sensitivity is low in the case of far-field and small signals (<0.15 mV), particularly in scar tissue where they may not be detected correctly. In such areas, global activation can be used as a surrogate, yet it may be difficult to distinguish reentrant activity from focal activity. 4) Reconstructed epicardial electrogram signals may be affected by tissues between the epicardium and body surface and specific anatomical conditions (high/low BMI, lung disease, limited coverage of the vest due to body habitus). 5) Transformation of data to phase-based analysis may demonstrate false reentrant activity because of interpolation of incomplete wave curvatures. To resolve this matter, local raw electrograms need to be checked manually to ascertain sequential propagation of regional waves. 6) Finally, reentrant and focal drivers detected by non-invasive body surface mapping were not validated by concurrent endocardial mapping, AF substrates are dynamic 3D structures with a range of discordance between the endocardial and epicardial tissue.<sup>41</sup> Hence further examinations will be needed to validate AF mechanisms including reentrant and focal drivers.

The non-invasive technique has been recently used to remap AF immediately after driver ablation. In fact, the critical point of driver-based ablation is to assess elimination of drivers after ablation. Moreover, incomplete RF application may not impact drivers or generate new AF substrate via slow conduction in the heterogenous region. In a small number of patients, we have shown the results of repeat mapping with different patterns (elimination, persistence and new appearance of driver) (see *Figure 4*).<sup>42</sup> *Figure 5* demonstrates a typical example of AF termination after repeat body surface mapping. A new reentrant driver appeared at the posterior of left superior PV on remapping AF persisting post driver ablation, AF was terminated by ablation in this area. Repeat non-invasive mapping provides important information on the dynamics of driver domains during ablation. Repeat

**Figure 5: Typical Example of AF Termination After Repeat Mapping**



Persistent atrial fibrillation (AF) (54-year-old male) with maximum AF duration of 5 months. AF persisted after ablation for all driver regions (left atrial septum, inferior, appendage, left superior pulmonary vein [PV]). Repeat mapping with body surface mapping revealed new reentrant driver region at the posterior of left superior PV (red dotted circle), AF terminated to sinus rhythm 20 seconds after RF application at this area (blue spot). LA = left atrium; LAA = left atrial appendage; LSPV = left superior pulmonary vein; RF = radiofrequency; SCI = shortest complex interval.

mapping can reveal residual and new drivers, which have the potential to increase the AF termination rate and improve clinical outcomes.

### Conclusion

Non-invasive AF mapping is feasible and guides ablation by providing panoramic beat-to-beat mapping to understand dynamic AF mechanisms. Driver-guided ablation promises equivalent clinical results with less RF time compared with stepwise ablation. Repeat AF mapping post-ablation may provide insights into the impact of ablation on drivers, emergence of residual or possibly new drivers and thereby improve this strategy of AF management. ■

### Clinical Perspective

- Localised reentrant and focal drivers play an important role in perpetuating atrial fibrillation (AF).
- Non-invasive body surface mapping visualises AF drivers in panoramic beat-to-beat mapping and enables understanding of dynamic AF mechanisms.
- Driver-guided ablation achieves similar AF termination rate with a relatively lesser extent of ablation than the stepwise approach, which may improve the clinical outcome in persistent AF.
- When AF persists after driver ablation, repeat mapping allows assessment of the impact of ablation on the drivers and detection of emerging or previously subduced drivers, which continue to maintain AF.

1. Calkins H, Kuck KH, Cappato R, et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. *Europace* 2012;**14**:528–606.

2. Swartz JF, Pellersels G, Silvers J, et al. A catheter-based curative approach to atrial fibrillation in humans. *Circulation* 1994;**90**:1–335.

3. Haïssaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ec-topic beats originating in the pulmonary veins. *N Engl J Med* 1998;**339**:659–66.

4. Haïssaguerre M, Jais P, Shah DC, et al. Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci. *Circulation* 2000;**101**:1409–17.

5. Pappone C, Rosanio S, Oreto G, et al. Circumferential

radiofrequency ablation of pulmonary vein ostia. A new anatomic approach for curing atrial fibrillation. *Circulation* 2000;**102**:2619–28.

6. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. *Circulation* 2004;**109**:327–34.

7. Jais P, Hocini M, Hsu LF, et al. Technique and results of linear ablation at the mitral isthmus. *Circulation* 2004;**110**:2996–3002.

8. Nademanee K, McKenzie J, Kosar E, et al. A new approach for catheter ablation of atrial fibrillation: Mapping of the electrophysiologic substrate. *J Am Coll Cardiol* 2004;**43**:2044–53.

9. Haïssaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. *J Cardiovasc Electrophysiol* 2005;**16**:1125–37.

10. Spach MS, Dolber PC. Relating extracellular potentials and their derivatives to anisotropic propagation at a microscopic

level in human cardiac muscle: evidence for electrical uncoupling of side to side fiber connections with increasing age. *Circ Res* 1986;**56**:356–71.

11. Spach MS, Boineau JP. Microfibrosis produces electrical load variations due to loss of side-to-side cell connections: a major mechanism of structural heart disease arrhythmias. *Pacing Clin Electrophysiol* 1997;**20**:397–413.

12. Rostock T, Drewitz I, Steven D, et al. Characterization, mapping, and catheter ablation of recurrent atrial tachycardias after stepwise ablation of long-lasting persistent atrial fibrillation. *Circ Arrhythm Electrophysiol* 2010;**3**:160–9.

13. Cuculich PS, Wang Y, Lindsay BD, et al. Noninvasive characterization of epicardial activation in humans with diverse atrial fibrillation patterns. *Circulation* 2010;**122**:1364–72.

14. Haïssaguerre M, Hocini M, Denis A, et al. Driver domains in persistent atrial fibrillation. *Circulation* 2014;**130**:530–8.

15. Jalife J, Berenfeld O, Mansour M. Mother rotors and fibrillatory conduction: a mechanism of atrial fibrillation. *Cardiovasc Res* 2002;**54**:204–16.
16. Haïssaguerre M, Hocini M, Sanders P, et al. Localized sources maintaining atrial fibrillation organized by prior ablation. *Circulation* 2006;**113**:616–25.
17. Narayan SM, Krummen DE, Eneyart MW, et al. Computational mapping identifies localized mechanisms for ablation of atrial fibrillation. *PLoS One* 2012;**7**:e46034.
18. Efimov IR, Nikolski VP, Salama G. Optical imaging of the heart. *Circ Res* 2004;**95**:21–33.
19. Cox JL, Canavan TE, Schuessler RB, et al. The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. *J Thorac Cardiovasc Surg* 1991;**101**:406–26.
20. Sahadevan J, Ryu K, Peltz L, et al. Epicardial mapping of chronic atrial fibrillation in patients: preliminary observations. *Circulation* 2004;**110**:3293–9.
21. Schuessler RB, Kawamoto T, Hand DE, et al. Simultaneous epicardial and endocardial activation sequence mapping in the isolated canine right atrium. *Circulation* 1993;**88**:250–63.
22. Kneller J, Zou R, Vigmond EJ, et al. Cholinergic atrial fibrillation in a computer model of a two-dimensional sheet of canine atrial cells with realistic ionic properties. *Circ Res* 2002;**90**:E73–E87.
23. Umapathy K, Nair K, Masse S, et al. Phase mapping of cardiac fibrillation. *Circ Arrhythm Electrophysiol* 2010;**3**:105–14.
24. Rudy Y, Burnes JE. Noninvasive electrocardiographic imaging. *Ann Noninvasive Electrocardiol* 1999;**4**:340–58.
25. Spach MS, Barr RC, Lanning CF, et al. Origin of body surface QRS and T wave potentials from epicardial potential distributions in the intact chimpanzee. *Circulation* 1977;**55**:268–8.
26. Durrer D, van Dam RT, Freud GE, et al. Total excitation of the isolated human heart. *Circulation* 1970;**41**:899–912.
27. Ramanathan C, Ghanem RN, Jia P, et al. Noninvasive electrocardiographic imaging for cardiac electrophysiology and arrhythmia. *Nat Med* 2004;**10**:422–8.
28. Haïssaguerre M, Hocini M, Shah AJ, et al. Noninvasive panoramic mapping of human atrial fibrillation mechanisms: a feasibility report. *J Cardiovasc Electrophysiol* 2013;**24**:711–7.
29. Shah AJ, Hocini M, Xhaet O, et al. Validation of novel 3-dimensional electrocardiographic mapping of atrial tachycardias by invasive mapping and ablation: a multicenter study. *J Am Coll Cardiol* 2013;**62**:889–97.
30. Hocini M, Shah AJ, Denis A, et al. Noninvasive 3D mapping system guided ablation of anteroseptal pathway below the aortic cusp. *Heart Rhythm* 2013;**10**:139–41.
31. Wang Y, Cuculich PS, Zhang J, et al. Noninvasive electroanatomic mapping of human ventricular arrhythmias with electrocardiographic imaging. *Sci Transl Med* 2011;**3**:98ra84.
32. Takahashi Y, Hocini M, O'Neill MD, et al. Sites of focal atrial activity characterized by endocardial mapping during atrial fibrillation. *J Am Coll Cardiol* 2006;**47**:2005–12.
33. Zellerhoff S, Hocini M, Dubois R, et al. Mechanisms driving paroxysmal AF displayed by noninvasive panoramic imaging (AB 35-05). *Heart Rhythm* 2013;**10**:S41–95.
34. Jadidi AS, Cochet H, Shah AJ, et al. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. *J Am Coll Cardiol* 2013;**62**:802–12.
35. Jadidi AS, Duncan E, Miyazaki S, et al. Functional nature of electrogram fractionation demonstrated by left atrial high-density mapping. *Circ Arrhythm Electrophysiol* 2012;**5**:32–42.
36. Narayan SM, Wright M, Derval N, et al. Classifying fractionated electrograms in human atrial fibrillation using monophasic action potentials and activation mapping: evidence for localized drivers, rate acceleration, and nonlocal signal etiologies. *Heart Rhythm* 2011;**8**:244–53.
37. Cochet H, Dubois R, Relan J, et al. Relationship between rotor activity and fibrosis in persistent atrial fibrillation: a combined noninvasive mapping and MRI study (PO 06-61). *Heart Rhythm* 2015;**12**:S512.
38. Haïssaguerre M, Sanders P, Hocini M, et al. Catheter ablation of long-lasting persistent atrial fibrillation: critical structures for termination. *J Cardiovasc Electrophysiol* 2005;**16**:1125–37.
39. Yamashita S, Hooks DA, Sellal J-M, et al. Characteristics associated with acute procedural success of ablation for persistent atrial fibrillation (PO 01-75). *Heart Rhythm* 2015;**12**:S126.
40. Knecht S, Sohal M, Arentz T, et al. Noninvasive mapping prior to ablation for persistent atrial fibrillation The AFACART multicenter study (PO 06-52). *Heart Rhythm* 2015;**12**:S508.
41. Gutbrod SR, Walton R, Gilbert S, et al. Quantification of the transmural dynamics of atrial fibrillation by simultaneous endocardial and epicardial optical mapping in an acute sheep model. *Circ Arrhythm Electrophysiol* 2015;**8**:456–65.
42. Yamashita S, Hooks DA, Sellal J-M, et al. Dynamic changes of drivers demonstrated by repeat non-invasive mapping during atrial fibrillation ablation (PO 01-77). *Heart Rhythm* 2015;**12**:S127.